Description
| Description | Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 nM, respectively. |
| Targets&IC50 | PD-L1/CD80:0.04 nM , PD-L1/PD-1:0.1 nM |
| In vivo | Durvalumab inhibits tumor growth in a mouse xenograft model of human melanoma (A375) and pancreatic (HPAC) tumor cell lines through a T-cell-mediated mechanism.The tumor growth inhibition of HPAC cells was 74% and that of A375 cells was 77%.Durvalumab had no effect on the growth of the A375 xenograft tumor in the absence of T cells. |
| Synonyms | MEDI 4736 |
| Molecular Weight |
N/A |
| CAS No. | 1428935-60-7 |
Storage
store at -20 ℃
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
